Bioinformatics Analysis Of FKBP11 In Clear Cell Renal Cell Carcinoma

Background:Renal cell carcinoma(RCC)is one of the 10 most common cancers in humans,and also one of the common malignant tumors of the urinary system.Its incidence is increasing year by year.The pathological types of RCC include chromophobe renal cell carcinoma,papillary renal cell carcinoma and clear cell renal cell carcinoma(ccRCC),etc.Among them,ccRCC is the most common pathological type of RCC,accounting for 70%～85%of renal epithelial tumors.Males have a higher incidence rate than females.For patients with early localized RCC,surgery is currently the first choice,and the survival rate can be effectively improved through surgical treatment.However,the early stage lacks typical clinical manifestations.Some patients progressed to the advanced stage at the initial diagnosis.For advanced RCC,there are many challenges in the clinical application of radiotherapy,chemotherapy,immunotherapy and molecular targeted therapy besides the lack of safe and efficient treatment.Although the 5-year survival rate has improved,the overall survival rate is still poor.For advanced patients with recurrence or metastasis,the survival rate is extremely low(5%-10%).Exploring new biomarkers and therapeutic targets for RCC is becoming increasingly urgent.FK506 binding protein(FKBP)is an intracellular specific receptor for the immunosuppressant FK506 and rapamycin.Rapamycin is an immune-suppressant that has recently been used as an anticancer drug.FKBPs play an important role in the development of a variety of tumor cells,including promoting cancer cell proliferation,migration,invasion and regulating cell apoptosis。FK506 binding protein 11(FKBP11)is a potential new marker found in glycine N-methyltransferase(GNMT)gene knockout mice.Researches has found that FKBP11 may be a potential early marker of hepatocellular carcinoma and maybe a high risk of melanoma and osteosarcoma.Based on this,it will be used as a basis for exploring new biomarkers and therapeutic targets for RCC.Objective:Using bioinformatics methods to explore the expression of FKBP11 in ccRCC,and analyze the correlation between FKBP11 expression and the clinical pathological characteristics of patients.And the effect of FKBP11 expression on the prognosis of ccRCC patients.To analyze the significance of FKBP11 for ccRCC..Methods:The Ualcan database was used to search the expression of FKBP11 in ccRCC and normal tissues,and analyze the correlation between its expression and the clinicopathological characteristics of ccRCC patients.The GEPIA database was used to analyze the expression differences of FKBP11 in human tumor tissues such as ccRCC tissues and normal tissues in the TCGA database,as well as its expression in ccRCC patients and its influence on the prognosis.The HPA database further analyzed the expression level of FKBP11 in ccRCC and its relationship with pathological grade,thus verifying the correlation between this gene and the prognosis of ccRCC patients.We hope to analyze the role of FKBP11 in ccRCC through these dimensions.Results:The expression of FKBP11 mRNA was higher in ccRCC than normal kidney tissues.The expression differences of FKBP11 between normal kidney tissues and ccRCC Grade 1,Grade2,Grade3,Grade4 were found through Ualcan database detection.The differences were P=5.78E-05,P=1.62E-12,P=1.11E-16,P=1.63E-12 respectively.The expression difference between normal kidney tissue and ccRCC subtype,ccA and ccB,was P=1.62E-12.Thehe expression differences between normal tissue and TNM stage,NO and N1,was P<1E-12,P=8.26E-05 respectively.The above differences were statistically significant(P<0.05).With the increase of ccRCC pathological grading,the expression of FKBP11 was up-regulated,indicating that the expression level may be related to the progression of ccRCC.However,there is no significance in age,sex and race(P>0.05).The overall survival rate of patients with high expression of FKBP11 was lower than that of patients with low expression of FKBP11(P<0.01).Conclusion:Through searching and analyzing the database information,it was found that the expression of FKBP11 mRNA was higher in ccRCC than normal kidney tissue.Differences were found in expression in different stages,pathological grades,and subtypes of ccRCC.The expression level of FKBP 11 was similar to the subgroups of age,gender,and race.There was no obvious difference between the subgroups of age,gender,and race.The expression of FKBP 11 was higher in poor pathological grades and stages.The subgroups of pathological subtypes,and the overall survival rate and tumor-free survival rate of ccRCC patients with high expression of FKBP 11 were worse than low expression patients.These results suggest that fkbp11 can be used as a potential biomarker for early diagnosis,staging and prognosis of ccRCC.